Galectin Therapeutics Inc.
Company Snapshot: Galectin Therapeutics Inc.
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- Dec 19 2017 Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019
- Dec 14 2017 Galectin Therapeutics Provides Corporate Update at Annual Meeting
- Dec 11 2017 Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders
- Dec 5 2017 Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial